Rod Raynovich's  Instablog

Rod Raynovich
Send Message
Rod Raynovich is an entrepreneur and executive with a focus on life science companies and medical technology trends.He has over 30 years executive experience including Abbott and JNJ and has been involved three successful start-ups. He has a B.S, from Penn State University and an MBA from... More
My company:
Raygent Capital
My blog:
  • Biotech Stocks Rally After Brief Sell-Off: INFI, PCYC 0 comments
    Feb 22, 2013 3:32 PM | about stocks: IBB, INFI, PCYC

    Technicals Still Rule As Momentum Eases

    The Life Science sector is up about 1% after two days of selling on heavy volume. The bellwether ETFs (IBB $145.16) are about 2% off 52 week highs and we do not expect this rally to surpass highs so caution is still recommended. Many of the larger cap MOmentum plays have blown off their tops and trying to stabilize. For example, Alexion (ALXN $87) had a blow-off top of $119 in October so is 27% off from 52 week highs; Regeneron (REGN $158.45) another favorite of hedge funds and BIG money has been losing momentum and is 15% off recent highs of $188.Medivation (MDVN $49.62 ) 0ff 0.44% continues weak off its 52 week high of $59.24 and the Company reports on Feb 28.

    As we noted on February 14 many of the winners from 2012 are down YTD and while the sector remains speculative with new money pushing stocks like Infinity (INFI $41.11) and Pharmacyclics (PCYC $89.61) higher there is a lot of stock distribution and profit taking. Our hedged trade recommendation of several months ago with MDVN short and PCYC long netted 40%++ profit depending when you got out.

    We would be adding to Gilead (GILD $42.28) on weakness but the shares are solid near all time highs. Cubist (CBST $42.42) is also strong just off early January highs and should be accumulated on weakness.

    Diagnostics and tools show a lot of green today with Abaxis (NASDAQ:ABAX), Alere (NYSE:ALR), Cardiovascular Sciences (NASDAQ:CSII) and Quidel (NASDAQ:QDEL) all holding up well technically.


    Two stocks illustrative of the biotech bull market is PCYC with a market cap of $6.2B but valuation and metrics do not matter if deals sound good and pipeline is robust. Same for Infinity Pharmaceuticals (NASDAQ:INFI) with a market cap of $1.6B with no Phase II data.

    Stocks: IBB, INFI, PCYC
Back To Rod Raynovich's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers


More »

Latest Comments

Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.